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Summary 
We dissected the T  cell activation potency and the immunoglobulin  (Ig) E-binding properties 
(allergenicity)  of nine isoforms of Bet v  1 (Bet v  1a-Bet v  11), the major birch pollen allergen. 
Immunoblot experiments showed that Bet v  1 isoforms differ in their ability to bind IgE from 
birch pollen-allergic  patients.  All patients tested displayed similar IgE-binding patterns toward 
each  particular  isoform.  Based  on  these  experiments,  we  grouped  Bet  v  1  isoforms in  three 
classes: molecules with high IgE-binding activity (isoforms a, e, and j), intermediate  IgE-bind- 
ing (isoforms b, c, and 0, and low/no  IgE-binding activity (isoforms d, g, and 1). Bet v  la, a re- 
combinant  isoform  selected  from  a  cDNA  expression  library  using  IgE  immunoscreening, 
exhibited the highest IgE-binding activity. Isoforms a, b, d, e, and 1 were chosen as representa- 
tives from the three classes for experimentation.  The potency of each isoallergen to activate T 
lymphocytes from birch pollen-allergic  patients  was assayed using peripheral  blood mononu- 
clear  cells,  allergen-specific  T  cell  lines,  and  peptide-mapped  allergen-specific  T  cell  clones. 
Among the patients,  some displayed a broad range of T  cell-recognition  patterns  for Bet v  1 
isoforms whereas others seemed to be restricted to particular isoforms. In spite of this variabil- 
ity, the highest scores for T  cell proliferative responses were observed with isoform d  (low IgE 
binder),  followed by b, 1,  e,  and  a.  In vivo  (skin prick)  tests showed  that the potency of iso- 
forms d and 1 to induce typical urticarial type I reactions in Bet v  1-allergic individuals was sig- 
nificantly  lower  than  for isoforms  a,  b,  and  e.  Taken  together,  our  results  indicate  that  hy- 
poallergenic Bet v  1 isoforms are potent activators of allergen-specific T  lymphocytes, and Bet 
v  1 isoforms with high in vitro IgE-binding activity and in vivo allergenicity can display low T 
cell antigenicity.  Based on these findings,  we propose a novel approach for immunotherapy of 
type I allergies: a treatment with high doses of hypoallergenic isoforms or recombinant variants 
ofatopic allergens. We proceed on the assumption that this measure would modulate the qual- 
ity of the T  helper cell response to allergens in vivo. The therapy form would additionally im- 
plicate a reduced risk ofanaphylactic side effects. 
I 
n  the last few years, cDNA cloning has provided a num- 
.ber of complete deduced amino acid sequences of atopic 
allergens  (1-4;  for review see reference 5).  The availability 
of nucleotide sequences and deduced amino acid sequences 
of allergenic  proteins  made  it possible  to reveal biological 
functions  and  to  characterize  the  structures  within  these 
molecules that interact with the human immune system (T 
and  B  cell  epitopes).  Bet  v  1,  the  model  allergen  used  in 
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this  study,  is  the  major  allergen  of birch  (Betula verrucosa) 
pollen  (6).  More  than  95%  of birch  pollen-allergic  indi- 
viduals display IgE binding to Bet v  1, and >60% react ex- 
clusively with it  (7). Bet v  1 belongs  to a  group  of patho- 
genesis-related  proteins  with  homologies  to  plant  disease 
resistance response gene products (3). 
T  cell epitopes are linear peptide fragments, and particu- 
lar  amino  acids  within  these  peptides  were  shown  to  be 
crucial  for  immunological  recognition  (MHC  binding, 
TCR  binding)  (8, 9). Several studies showed that atopic al- 
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complete  amino  acid sequence  (10-19).  Moreover,  it has 
been demonstrated that allergic and nonallergic individuals 
display a polyclonal T  cell response to the epitopes of one 
allergenic protein.  Some T  cell epitopes seemed to repre- 
sent "major epitopes," as almost every sensitized individual 
recognized these sequences. Identification orB cell epitopes, 
on the other hand,  has only been partly successful. This is 
obviously because  B  cell  epitopes  represent--with  a  few 
exceptions  (20,  21)--conformational  structures  and  are 
therefore difficult to identify. In the case of our model al- 
lergen Bet  v  1,  fragments  obtained by chemical or  enzy- 
matic treatment of the molecule were not reactive with IgE 
antibodies (6), and only complete clones were reactive with 
IgE,  indicating the relevance of structural features in anti- 
body binding to this protein (22). 
Allergenic pollen proteins consist of a mixture of closely 
related  isofomls,  as  was  shown  in  most  cases  by  cDNA 
cloning.  Isoforms  have  been  described for  Arab  a  1,  the 
predominant  allergen from  short  ragweed  (Ambrosia  arte- 
misiifolia) pollen (23), for Poa p  9, a group of basic isoaller- 
gens from Kentucky bluegrass (Poa pratensis) pollen (24), for 
Car b  1,  the major allergen from hornbeam (Carpinus  betu- 
lus) pollen (25), for Cot a  1,  the major allergen from hazel 
(Corylus avellana)  pollen (26), and for Bet v  1 (27). The ex- 
istence ofisoforms of Bet v  1 in birch pollen was confirmed 
at the protein level by mass spectrometry (27). 
In this study we  have  addressed the  subject of isoaller- 
gens and their interactions with the immune system of pol- 
len-allergic individuals.  Previous  studies  described  differ- 
ences  in  the  antibody  (IgE)-binding properties  of pollen 
isoallergens (26, 28, 29)  and invariably focused on isoaller- 
gen molecules with high IgE-binding activity, because this 
property is  considered essential for  allergenicity of a  pro- 
tein.  Strong  IgE-binding  isoforms,  however,  might  not 
necessarily represent potent activators of T  cells. To deter- 
mine  whether  high  IgE-binding activity of an  individual 
isoallergen correlates to high T  cell antigenicity, isoforms of 
Bet v  1 were  tested for both properties. To  define exactly 
the role of each isoallergen in the activation of T  lympho- 
cytes  from  allergic  patients,  we  performed  assays  using 
PBMC,  allergen-specific T  cell lines (TCL)]  and allergen- 
specific T  cell clones  (TCC).  It  can be  foreseen  that  this 
knowledge will be important for the development of ade- 
quate  reagents  for  immunotherapy  of pollen-allergic pa- 
tients.  Based  on  the  results  presented  here,  we  suggest  a 
new concept for immunotherapy of type I allergic diseases. 
Materials and Methods 
Birch Pollen Extract.  Protein extract from birch  (B.  verrucosa) 
pollen (Allergon AB, Engelhom, Sweden) was prepared as previ- 
ously described (30). 
1Abbreviations used in  this paper: MALDI-TOF, matrix-assisted laser de- 
sorption/ionization time of flight; nBet v 1, natural Bet v 1; SIT, specific 
immunotherapy; SPT, skin prick test; TCC, T cell clones; TCL, T cell 
lines. 
SDS-PAGE and Immunoblots.  Birch pollen protein extract and 
Escherichia coli lysates of recombinant Bet v  1 isoforms were ana- 
lyzed by SDS-PAGE according to the method of Laemmli (31), 
using 15% acrylamide gels. Proteins were visualized by staining 
with Coomassie brilliant blue R-250.  As the level of expression 
varied for each Bet v  i  isoform, Coomassie-stained gels were an- 
alyzed on  an  imaging densitometer  (model  GS-670;  Bio-Rad 
Laboratories, Richmond, CA), and peak areas were measured. In 
this  way,  it was  possible to  calculate  the  amount  of lysate  to 
achieve equivalent amounts for each isoform in immunoblot ex- 
periments. 
For  immunoblot  analysis,  proteins  were  separated  by  15% 
SDS-PAGE  and  electroblotted  (32)  onto  nitrocellulose mem- 
branes. IgE immunoblots were performed as described previously 
(7).  Bound  IgE was  detected using 125I-rabbit anti-human  IgE 
(Pharmacia, Uppsala, Sweden). E.  coli lysates harboring the plas- 
mid without insert were used as a control. In all experiments, re- 
agents and cell lysates were from identical batches and were used 
in the  same concentrations. Autoradiography was  performed at 
-70~  for 12-48 h with intensifying screens. 
Purification of Natural Bet v  I.  Natural Bet v  1 (nBet v  1) was 
purified from aqueous extract of birch (B. verrucosa) pollen (Aller- 
gon AB) by reversed-phase HPLC (C8 Hypersil WP 300,  10 Ixm, 
8 X 250 ram) using a linear gradient of 2-propanol at room tem- 
perature (solvent A: aqueous 0.1% TFA; solvent B: aqueous 90% 
2-propanol/0.1% TFA; gradient 0--80% B  within 50  min;  flow 
rate  1.8  rnl/min).  UV  absorbance  was  monitored  at  280  nm. 
Fractions (2 ml) were collected, dried in vacuo, and resuspended 
in water. Aliquots were analyzed by SDS-PAGE and immuno- 
blots using mAbs and allergic patients' sera (7, 30). 
Cloning  of Recombinant  Bet v  1 Isoforms as Nonfusion  Proteins in 
pMW175/I72.  Expression plasmids  containing cDNA  inserts 
coding for Bet v 1 isofonns were constructed in the vector pMW175 
or pMW172 (33), which are based on the original pET vectors of 
Studier et al. (34). These vectors direct the synthesis ofa nonfusion 
protein under the control of the T7 promoter. In this system, T7 
polymerase is under control of the lacUV5 promoter, leading to 
inducible production of the recombinant protein. The nucleotide 
sequences and derived amino acid sequences of nine isoforms of 
Bet v 1 have been described elsewhere (Bet v I a, reference 3; Bet 
v 1b-g, j  and 1, reference 27).  The 5' primers B-1  (5'GGGCCA- 
TGGGTGTTTTCAATTACGA3')  and B-3  (5'GGGCATATG- 
GGTGTTTTCAATTACGA3') and the 3' primer B-2 (5'CCC- 
GAATTCTTAGTTGTAGGCATCAGAGTGTGCCAA3') were 
used in a PCR_ with cDNAs coding for Bet v  1 isoforms to pro- 
duce DNA fragments without 5' and 3' nontranslated sequences 
and with appropriate recognition sequences  at their 5' and 3' ends. 
The primer B-1 encoded six NH2-terminal amino acids (identical 
in all Bet v  1 isoforms) and had an NcoI site at its 5' end. The 
primer B-3 was similar to B-1  except that it had an Ndel site at its 
5'  end. The primer B-2 encoded eight COOH-terminal amino 
acids (identical in all isoforms) and had an EcoRI site at its 5' end. 
The resulting NcoI-EcoRl coding sequences (Bet v I a-f, j, and 1) 
were inserted into NcoI-EcoRI--digested  pMW175 vector and the 
Ndel-EcoRI coding sequence (Bet v lg) inserted into the Ndel- 
EcoP,  I-digested pMW172  vector.  These  expression  constructs 
were designated pMW175/Bet v la-f, j, and 1 and pMW172/Bet 
v  lg, respectively. All PCR-derived inserts were sequenced ac- 
cording to the dideoxy chain termination method (35). 
Expression and  Preparation of E.  coil Cell  Lysates  of rBet  v  1  lso- 
forms.  For  expression  of the  pMW175/Bet  v  1a-f,  j,  1,  and 
pMW172/Bet v lg plasmids, competent E. coil strain BL21 (DE3) 
was  transformed and selected on plates containing  100  rag/liter 
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grown to an OD600 of 1.0.  Isopropyl-f3-D-thiogalactopyranoside 
was then added to a final concentration of 1.0 raM, and incuba- 
tion was continued for 6 h  at 37~  After expression, cells were 
harvested by centrifugation, and pellets were  resuspended in 50 
mM  Tris-HCl,  pH  7.5,  containing 220  mM  NaCI  (buffer A). 
The cells were then disrupted by freezing in liquid nitrogen fol- 
lowed by thawing at  37~  This step was  repeated  twice.  Iso- 
forms a and e were recovered in the supernatant after centrifuga- 
tion at  30,000 g  for  25  rain at  4~  which  was  then used  for 
immunoblot analysis. Isoforms b-d, f, g, j, and 1 were recovered 
in  the  pellet  by  low-speed  centrifugation.  Insoluble  inclusion 
bodies were solubilized in buffer A containing 6 M  urea and dia- 
lyzed at 4~  against buffer A. After dialysis, the extracts were used 
for immunoblot experiments. In a previous publication (22),  we 
have  shown by quantitative ELISA inhibition experiments that 
denaturation of Bet v  1 in 6 M  urea and renaturation by dialysis 
does not affect IgE binding. 
Purification ofrBet v  I lsoforms,  rBet v  1 isoform a was purified 
from crude E. coli lysates by a combination of chromatofocusing 
on a PBE-94  (Pharmacia) exchanger column and reversed-phase 
HPLC, as previously described (22). rBet v 1 isoforms b, d, e, and 
1 were  purified using the  method  described for rBet v  la  (22), 
with few modifications. Briefly, bacteria! lysates were prepared in 
25  mM imidazole/HCl buffer containing 6  M  urea  (buffer C). 
The  extracts  were  loaded  onto  a  PBE-94  exchanger  column 
equilibrated with buffer C, at room temperature. Bound proteins 
were  eluted with  aqueous  12.5%  (vol/vol)  Polybuffer 74/HC1 
(Pharmacia),  pH  4.0,  containing 6  M  urea,  as  previously  de- 
scribed  (36).  Fractions containing rBet  v  1  isoforms,  as  deter- 
mined by dot blot immunoassays using mAbs, were pooled and 
subjected to reversed-phase HPLC, as described previously (22). 
Protein  concentrations  of  all  purified  allergen  preparations 
were determined by the micro-Kjeldahl method, using glycine as 
standard (37). 
NH2-terminal Sequence Analysis.  Birch pollen extract and E. coli 
lysates  of Bet v  1 isoforms were  separated by  15%  SDS-PAGE 
and blotted onto polyvinylidene difluoride membrane (Millipore 
Corp., Bedford, MA). Bands corresponding to nBet v  1 (a mix- 
ture of isoforms) or rBet v  1 isoforms were excised and proteins 
eluted by incubation with  40%  (vol/vol)  acetonitrile and  30% 
(vol/vol) TFA for  1 h  at room temperature.  Samples were vac- 
uum dried, resuspended in water, and sequenced with a protein 
sequencing system (G1005AQ; Hewlett-Packard Co., Palo Alto, 
CA). Protein samples were loaded directly onto the hydrophobic 
part  of the biphasic sequencer column and subjected to  Edman 
degradation using the manufacturer's Routine 3.0 chemistry. 
Matrix-assisted  Laser  Desorption/Ionization  Time-of-Flight  Mass 
Spectrometry.  0.5 p,1 of purified isoforms was mixed with 2.5 ILl 
protein calibration standard (cytochrome c, myoglobin, and BSA) 
and 6 p~l of sinapinic acid containing citric acid as chelator. After 
vacuum crystallization, samples were subjected to matrix-assisted 
laser desorption/ionization time-of-flight (MALDI-TOF) analysis 
using a  MALDI-TOF  system  (HP  G2025A;  Hewlett-Packard 
Co.) equipped with a nitrogen laser. 
Allergen-speeific TCL.  Allergen-specific  TCL  were  obtained 
by  a  technique  described  previously  (14).  Briefly,  0.5  ￿  106 
PBMC  were  stimulated with individual optimal concentrations 
(5-20  Ixg/ml)  of purified  nBet v  1  in Ultra  Culture Medium 
(BioWhittaker,  Inc.,  Walkersville,  MD)  supplemented  with  2 
raM/liter glutamine and 2  ￿  10 -s M  2-ME in 24=well flat-bot- 
tomed  culture  plates  (model  3524;  Costar  Corp.,  Cambridge, 
MA) for 5 d. Subsequently, human rlL-2 (10 U/ml, Boehringer 
Mannheim, Mannheim, Germany)  was  added,  and the  culture 
was continued for an additional 7 d. 
Allergen-specific T Cell Clones.  T cell blasts from nBet v 1-specific 
TCL were seeded in limiting dilution (0.3 cells/well) in 96-well 
round-bottom plates (Nunclone; Nunc, Roskilde, Denmark) in 
the  presence  of 10  s  irradiated  (5,000  rad)  allogeneic PBMC  as 
feeder cells,  1% PHA vol/vol (Gibco Laboratories, Grand Island, 
NY),  and  rlL-2  (4  U/well)  in  the  above-described  medium. 
Growing microcultures were  then expanded at weekly intervals 
with fresh feeder cells and rlL-2. The specificity of TCC was as- 
sessed as previously described (14).  Briefly, 2  ￿  104 T  cell blasts 
were incubated in triplicate cultures in 96-well plates in the pres- 
ence of 105 autologous irradiated PBMC with one of the follow- 
ing ingredients: whole birch pollen extract,  purified nBet v  1, 
rBet  v  la,  or  overlapping Bet  v  la  peptides.  Microtiter plates 
were then incubated for 48 h at 37~  in a 5% CO2 humidified at- 
mosphere. After pulsing for 16 h  with [3H]TdR, cells were har- 
vested, and the incorporated radioactivity was measured by scin- 
tillation counting. When  the  stimulation index  (ratio  between 
cpm obtained in cultures with TCC  plus autologous irradiated 
PBMC  plus  antigen and  cpm  obtained  in  cultures  containing 
TCC  and PBMC  alone)  was  >10,  responses  were  considered 
positive. 
Proliferation Assays.  PBMC  and nBet v  1--specific  TCL  and 
TCC were tested with nBet v  1, with two recombinant Bet v  1 
isoforms displaying high IgE-binding capacity (rBet v la and rBet 
v  le; see Fig. 2),  two recombinant isoforms diplaying low IgE- 
binding properties  (rBet v  ld and rBet v  11; see Fig. 2),  and an 
isoform displaying intermediary levels of IgE binding (rBet v  lb). 
All proliferation assays were  performed in triplicate; incubation 
periods before addition of [3H]TdR were 6 d for PBMC and 48 h 
for  TCL  and  TCC,  respectively.  In  all  experiments,  identical 
concentrations of allergen (1 p,g/well =  5 p,g/ml) were used. 
Epitope Mapping.  T cell epitope mapping was performed in TCC 
reactive with rBet v  la, using 50 peptides (Cambridge Research 
Biochemicals  Limited,  Cambridge,  UK)  overlapping for  three 
amino acids and spanning the whole sequence of the protein (14). 
Analysis of the Phenotype of TCC.  FITC-labeled mAb anti-Leu 
4/CD3,  anti-Leu 3a/CD4,  anti-Leu 2a/CD8,  anti-TCR-1  a/b 
WT31, and anti-TCR g/d I  (Becton Dickinson &  Co., Moun- 
tain View, CA) were used to analyze the phenotype of the TCC. 
For  flow  cytometry  analysis,  TCC  and  irradiated  feeder  cells 
alone were  harvested and washed,  and 10  s cells  were  incubated 
for 30 rain on ice with the appropriate dilution of mAb or iso- 
type-matched control Abs. After washing three times with PBS 
containing 0.3% BSA and 0.3% NaN  3, the cells were stained with 
propidium bromide to allow exclusion of dead cells and analyzed 
on a FACScan  |  (Becton Dickinson & Co.). 
Skin Testing with Purified rBet v 1 Isoforms.  Skin prick test (SPT) 
was performed according to guidelines described (38).  For SPT, 
100 ng/25 Ful of each isoform (39) and commercially available test 
solutions  (birch  pollen extract,  grass  pollen  extract,  histamine, 
0.9% sodium chloride) were applied. For comparison, computer- 
aided measurements of wheal areas were performed. Skin testing 
of birch  pollen-allergic individuals with  recombinant Bet  v  1 
molecules was approved by the Ethics Committee of the Univer- 
sity of Vienna, Austria. 
Results 
Expression  of Bet  v  1  Isoforms,  IgE-binding  Properties,  and 
Purification of Bet v  1 Isoforms.  Nonfusion  forms  of  fun- 
length cDNAs  coding for nine Bet v  1  isoforms were  ex- 
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E.  coli and  MALDI-TOF  mass spectrometry 
analysis  of purified  isoforms.  (a)  Coomassie- 
stained  15%  SDS-PAGE  of lysates  of E.  coli 
BL21(DE3)  host strain containing Bet v  1 iso- 
forms  expression  plasmids. (Lane c) Host strain 
lysate containing the expression vector without 
an insert;  (lanes  I-9)  Bet v  1 isoforms  a-g, j, 
and I, respectively. (b) MALDI-TOF mass spec- 
tra of purified recombinant Bet v  1 isoforms a, 
e, d, and 1. m, myoglobin (16,944.0 daltons) was 
added to the Bet v le preparation  as an internal 
molecular mass standard. 
pressed in  E.  coli  (Fig.  1  a).  High  levels of expression  (be- 
tween  20  and  100  mg  protein  per  liter  bacterial  culture) 
were  obtained.  NH2-terminal  sequence  analysis  of all  re- 
combinant  isoforms  showed  that  the  initiating methionine 
was removed. 
To  evaluate  the  ability of recombinant  Bet v  1  isoforms 
to  bind  IgE  from  allergic  patients,  immunoblot  experi- 
ments  were performed.  In total, sera from 30 patients were 
tested.  Fig. 2  shows  the  IgE-binding patterns  of eight rep- 
resentative  allergic  individuals  with  each  isoform.  In  gen- 
eral,  isoforms  a-c,  e-f,  and j  displayed  good  IgE-binding 
reactivity.  Among  these,  isoforms  a,  e,  and j  were  promi- 
nent  in  this  respect  (Fig.  2).  Most  interestingly,  sera  of all 
patients  tested  failed  to  recognize  or  showed  remarkably 
low  IgE  binding  to  isoforms  d,  g,  and  1  (Fig.  2).  Taking 
rBet  v  la  as  a  reference  (100%  IgE  binding),  the  relative 
percentage  of IgE binding for the other isoforms was calcu- 
lated (see Table 2). 
Five  isoforms  were  selected  for  detailed  experiments 
concerning activation of T  lymphocytes from allergic indi- 
viduals.  For this purpose,  the  chosen  isoforms  (isoforms  a, 
b, d,  e, and 1) were purified to homogeneity,  as determined 
by  SDS-PAGE  (data  not  shown).  The  purified isoallergen 
preparations  were  further  analyzed  by MALDI-TOF  mass 
spectrometry  (Fig.  1  b). The  molecular masses of intact Bet 
v  1  isoforms  a,  d,  e,  and  1 were  measured  as  17,438.6, 
17,413.7,  17,320.5,  and  17,426.0,  respectively.  The  theo- 
retical molecular masses  obtained,  based  on  the  cDNA  se- 
quences,  were  17,439.62  (Bet v  la),  17,417.68  (Bet v  ld), 
17,316.55  (Bet  v  le),  and  17,421.73  (Bet  v  11). Thus,  the 
experimental molecular mass measurements  are in excellent 
agreement  with  the  expected  mass  values.  The  measured 
mass values  are also consistent  with the  removal  of the  ini- 
tiating methionine. 
For an estimation of the relative amounts  of the different 
Bet v  1  isoforms  in the  pollen washout,  NH2-tenninal  se- 
quence  analysis  of purified  nBet  v  l  was  performed.  The 
Figure 2.  IgE immunoblot of recombinant Bet v 1 isofonns. Sera from 
birch pollen-allergic patients 1-8 were tested for IgE binding to recombi- 
nant Bet v 1 isoforms expressed in E. coli BL21. Bacterial lysates contain- 
mg the  expression  vector without an  insert  were used  as controls  (not 
shown). 
602  Human  IgE and T  Lymphocyte Reactivity of Bet v  1 lsoallergens Table  1.  Proliferative Responses of Human Bet v  l-Specific  TCC to nBet v  I and rBet v  1 Isoforms Presented by Autologous  PBMC 
Patient  TCC  Control  nBet v  1  rBet v  la  rBet v  le  rBet v  lb  rBet v  l d  rBet v  11 
1  XPC2  0.1  +  0  50.5  +3  0.1  +  1  2.2  +  1  5.6-+2  12.2  +2  16,9_+2 
XPC3  0.2  +  0  21.3  +  4  49.7  +  5  63.0  -+ 3  11.9  +  3  39.4  "+ 2  47.2  -  6 
XPC8  0.1  .+ 0  2.1  .+ 0  8.1  +  0  5.2  ,+  1  1.1  +  0  13.0  .+ 2  15.3  ,+ 3 
XPC26  0.2  +  0  21.1  .+ 3  32.4  .+ 4  tl.5  .+ 0  43.6  +  6  7.6  .+  1  39.2  _+  17 
XPC31  0.2  -+ 0  23.5  .+  1  19.6  +  5  21.9  ~  i  0.2  ,+ 0  20.6  .+  1  25.1  +  5 
XPC33  0.3  .+ 0  33.4  ,+ 2  18.8  +  4  4.1  +  0  38.9  +  5  34.4  .+ 0  39.2  _  I 
2  XPFI  0.1  .+  0  74.9  +  0  44.6  ,+ 2  99.2  .+  11  73.1  +  5  95.6  ,+  5  107.8  ,+  1 
XPF7  0.2  .+  0  95.0  +  7  7.7  +- 0  105.2  .+  10  66.0  -+  3  165.6  ,+  21  1.0  +  0 
XPF10  0.2  ,+  0  1.8  +  0  21.0  .+  0  9.6  ,+  0  7.3  -4-- 0  9.3  .+  1  15.8  .+ 2 
XPF5II  0.1  +  0  7.8  -+  l  0.1  .+  0  0.1  +  0  10.5  .+  0  10.2  .+  0  0.1  _+  0 
XPF10II  0.7  +  0  8.2  "+ 0  4.1  "+  0  7.4  +  0  9.2  -+  0  3.3  .+  0  9.8  _+  1 
XPF62II  0.1  .+  0  15.6  ,+  2  0.1  -+  0  0.1  ,+  0  3.4  ,+  1  8.0  _+  0  0.1  .+  0 
XPF77II  0.1  .+  0  1.3  _+  0  5.2  .+  1  14.8  +  0  16.0  _+  6  10,0  .+ 0  14.1  .+ 0 
XPF113II  0.1  --_  0  6.1  -4-  1  0.1  .+  0  0.1  -  0  0.1  -+  0  0.1  .+  0  0.1  ,+  0 
3  XPH8  0.4  _+  0  48.0  ,+  14  10.5  -+  1  52.6  -+  2  66.5  ,+  2  67.0  +  2  88.3  .+  4 
XPH23  0.3  ,+  0  5.2  "+ 0  1.2  ,+  0  2.1  _+  0  0.1  _  0  12.7  .+  1  20.0  _+  3 
4  XPD18  0.1  +  0  0.7  "+  0  26.3  .+  2  0.2  +  0  102.0  ,+ 39  11.9  .+  6  0.4  ,+  0 
XPD22  0.1  +  0  46.0  .+ 20  28.9  "+  5  0.2  _+  0  147.1  .+ 24  10.9  ,+  1  0.3  .+  0 
XPD24  0.9  "+ 0  98.2  ,+  5  70.7  ,+  1l  77.0  ,+  15  85.1  .+  6  86.9  ,+  2  77.4  +  8 
XPD25  0.1  -+  0  78.4  ,+  2  24.4  .+  1  81.8  -  9  65.7  +  4  87.2  .+ 6  64.2  .+ 2 
XPD27  1.1  +  1  77.8  .+  16  14.7  .+  2  0.2  _  0  128.5  +  3  4.1  .+  2  0.2  ,+  0 
5  XPWF17  0.1  ,+  0  145.3  -+  12  83.8  +  3  11.2  +  2  168.6  -+ 21  167.7  .+  11  167.3  -+  2 
XPWF24  0.1  _+  0  40.3  -+  2  25.4  ,+  3  25.0  .+  1  42.4  .+ 2  42.8  .+ 2  46.8  ,+  1 
XPWF29  0.1  _2-  0  45.8  ,+  10  14.8  ,+  2  53.5  .+  3  0.3  ,+  0  93.7  _-2- 5  122.6  ,+  6 
XPWF39II  0.1  .+  0  29.2  ,+  l  5.4  +  2  19.2  .+  1  17.1  ,+  3  32.2  ,+  4  19.7  _+  6 
6  XPR4  2.3  .+  1  208.8  .+  51  152.6  +  12  201.3  .+  7  240,5  .+  5  224.5  _+  2  204.2  .+  18 
XPR4II  5.5  .+  1  201.1  -+  12  5.4  ,+  2  6.3  -+  2  82.2  •  6  160.0  .+ 20  4.2  .+  1 
XPR6  0.2  .+ 0  24.3  .+  3  9.5  -  l  17.8  ,+  1  25.4  .+  2  20.4  .+  3  17.5  +  1 
XPR9  0.8  .+  0  79.6  .+  2  66.4  -+  4  34.3  ,+  2  86.6  ,+  3  111.7  ,+  2  50.6  ,+  3 
XPRI1  2.8  .+  1  108.7  ,+  9  2.8  •  0  2.1  ,+  1  81.7  .+  9  161.9  +  3  0.9  -+  0 
XPR16  0.5  .+  0  23.8  +  2  0.7  +  0  0.7  .+  0  13.2  ,+  4  47.6  .+  I  0.3  +  0 
XPR29  3.9  ,+  1  75.4  +  21  2.5  .+  0  2.8  .+  1  44.4  ,+  8  123.4  _+  14  1.6  .+  0 
XPR44  2.4  _+  0  173.3  ,+  7  3.5  ,+  1  2.1  ,+  1  92.9  .+ 31  170.1  _+  7  1.9  -+  0 
XPR51  0.2  .+  0  217.0  _4_- 13  0.3  .+  0  215.4  .+  11  287.3  .+  6  84.4 .+  6  1.3  _-2-  1 
XPR86  2.4  -+  1  95.0  .+ 38  2.6  +  1  1.1  .+  0  11.5  _+  0  73.9  -+  5  0.8  _+  0 
7  XPZIO  0.7  ,+  0  7.5  +  0  6.6  ,+  1  6.4  _+  1  6.5  .+  1  6.1  _+  0  6.1  _+  {1 
XPZ11  0.7  .+  0  9.6  2  1  0.5  +  0  9.2  .+  1  11.3  .+  0  6.5  _+  1  3.7  .+  1 
XPZ31  0.1  +  0  58.7  2  17  3.3  ,+  0  30.6  ,+  1  7.1  _+  2  37.7  .+  0  42.5  .+  3 
XPZ53  0.1  -  0  8.2  7-  3  9.4  .+ 4  8.5  +  3  8.4  •  3  8.7  -4-  3  8.7  ,+  3 
8  XPGZIO  0.1  2  0  12.5  ,+ 4  3.1  .+  1  26.8  +  8  0.1  _+  0  25.8  -+  8  37.3  2  10 
XPGZ16  0.i  +  0  110.3  ,+ 30  85.4  .+ 23  114.9  ,+  31  77.8  _+  21  102.3  .+  28  89.8  .+  27 
XPGZ17  0.1  +  0  18.0  +  5  12.8  .+  4  18.0  _+  5  0.2  .+  0  27.7  _+  8  44.8  -+  13 
XPGZ17II  0.5  +  0  45.7  +  13  0.2  .+  0  0.6  .+  0  12.2  .+  3  7.0  _+  2  43.2  .+  16 
XPGZ29  0.1  •  2  31.9  .+  9  20.4  ,+  6  25.6  .+  7  28.l  .+  8  31.9  +  9  31.4  _+  9 
XPGZ62  5.7  ~  0  53.3  .+  15  0.4  ,+  0  33.4  .+  9  49.7  -+  14  43.3  ,+  12  7.3  -+  2 
XPGZ64  0.6  -+  0  48.7  2  14  0.1  .+  0  14.8  -  4  54.3  .+  15  25.9  .+ 7  1.5  .+  0 
XPGZ70  2.6  •  1  33.8  ,+  9  0.2  .+  0  13.6  .+  4  26.3  .+  8  18.8  .+  5  2.3  ,+  1 
KPGZ72  4.1  .+  1  33.9  .+  9  0.2  +  0  28.2  .+  8  25.8  _+  7  33.3  -+  9  6.1  +  2 
Control: TCC  +  irradiated autologous PBMC,  no antigen. Values are cpm X  103  ~- SD. Boldface values indicate negative proliferative responses. Figure 3.  Experimental strategy and results of T lymphocyte stimula- 
tion experiments. As an example, T cell reactivity patterns of  patient 7 are 
shown (see Fig. 2 and Table 1). Bars are stimulation indices obtained with 
rBet v 1 isoforms  a, b, d, e, and 1  and with pollen Bet v 1 (nat). 
results clearly indicated that the naturally occurring Bet v  1 
isoforms have their initiating methionine removed and start 
with the glycine residue. A single sequence was determined 
until  residue  7,  where  serine,  threonine,  and  isoleucine 
were detected at a ratio of~2:2:1  (data not shown). In po- 
sition 9, threonine and alanine were detected at a ratio of 6: 
1.  From this  experiment and from our previous analysis of 
proteolytic  digests  of nBet v  1 by mass spectrometry  (24), 
we estimated that isoforms a and b  represent "o35% of pol- 
len  Bet  v  1,  whereas  isoforms  d  and  f  seem  to  represent 
~10% each. Together, isoforms a-c, e, f, andj represent up 
to 80% of total Bet v  1 released from birch pollen upon hy- 
dration. 
Polyclonal T  Cell ReactMty with Bet v  1 Isoforms.  Responses 
of freshly isolated PBMC to five isoforms (a, b, d, e, and 1) 
were analyzed in 15 birch pollen-allergic patients.  Individ- 
ual  reactivity  patterns  could  be  observed  reflecting  the 
polyclonal  nature  of T  cell  recognition.  Bet  v  1--specific 
TCL were established using purified natural Bet v  1, a mix- 
ture ofisoallergens. In general, results obtained in prolifera- 
tion assays using n_Bet v  1-specific TCL reflected the reac- 
tivity pattern toward each isoform seen in PBMC. However, 
reactivity patterns to Bet v  1 isoforms differed among indi- 
viduals. A schematic representation of the experimental ap- 
proach is shown in Fig. 3. 
Bet v  1-specific  TCC.  48 TCC were tested for reactivity 
with 5 recombinant Bet v  1 isoforms (a, b, d, e, and 1). All 
TCC revealed the Th phenotype (CD3+CD4+CD8 -)  and 
expressed  TCR-c~/[3.  Results  of T  cell  proliferation  are 
summarized in Table  1. Different patterns  of cross-reactiv- 
ity  between  the  isoforms  could  be  observed.  Based  on  a 
stimulation index >  10, 47 of 48 (98%)  TCC proliferated in 
response  to  stimulation  with  purified  nBet  v  1,  28  of 48 
(58%)  reacted with  rBet v  la,  34 of 48  (71%)  reacted with 
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Figure 4.  Epitope  specificlties and proliferative responses of 27 Bet v 
1-specific TCC. (a) Amino acid sequence alignment of five Bet v 1 iso- 
forms. Highlighted boxes indicate T cell epitopes identified using over- 
lapping peptides synthesized according to the Bet v la sequence. (b) Bars 
show stimulation indices of 27 TCC (grouped according to the epitope 
recognized) with rBet v 1 isoforms  a, b, d, e, and I and with pollen Bet v 
1 (nat). 
rBet v  le, 41  of 48  (85%)  reacted with rBet v  lb,  45 of 48 
(94%)  reacted  with  rBet  v  ld,  and  29  of 48  (60%)  re- 
sponded to rBet v  11.  Interestingly,  only 39% of TCC  re- 
acted with all isoforms investigated.  One TCC  (XPF11311, 
patient  2,  Fig.  1)  failed  to  recognize  any  of the  selected 
recombinant molecules in spite ofreactvity with nBet v  1. 
27  TCC  displaying reactivity with  rBet  v  la  were  ana- 
lyzed for epitope  specificity using overlapping peptides.  In 
total,  eight  T  cell  epitopes  recognized  by  different  TCC 
were identified  (Fig. 4). Positions and frequencies of T  cell 
epitopes were in accordance with our previously pubhshed 
results  (14,  15,  40).  In several cases,  amino acid differences 
between  different isoforms of Bet v  1 caused decreased re- 
activity or nonreactivity in particular TCC recognizing the 
corresponding isoform sequence. For instance, crucial amino 
acid differences in the sequence representing epitope 4 and 
epitope 7 in isoform B  in general led to decreased recogni- 
tion of this isoform by TCC reactive for these epitopes. On 
the other hand, epitopes that were well conserved through- 
Human lgE and T Lymphocyte Reactivity of Bet v 1 lsoaUergens Table 2.  Human IgE and  T  Cell Reactivity Patterns of Bet v  1 
Isoforms a, e, b, d, and I 
T cell  Skin prick test 
reactivity  lgE binding  wheal areas 
(rel.%)  (rel. %)  (mm  2) 
nBet v 1  100  100  ND 
rBet v la  41  100  70 
rBet v le  67  83  50 
rBet v lb  92  60  19 
rBet v ld  100  5  7 
rBet v 11  87  3  10 
T cell reactivity values are relative percentages of added stimulation in- 
dices (48 TCC) taking nBet v I  as reference. Relative percentages of 
IgE binding in immunoblots (sera from 30 patients) were calculated tak- 
ing nBet v 1 and rBet v la as references. Values of wheal areas in skin 
prick tests are the average for five patients. ND, not determined. 
out the sequences of these five isoforms seemed to be rela- 
tively well recognized by all TCC reactive with these pep- 
tides, for example, epitopes 3 and 8. In several cases, because 
of individual  factors,  no  uniformity within  reactivity pat- 
terns  toward the  same  epitope  was  evident.  For example, 
reactivity ofTCC XPR6 was not affected by an amino acid 
exchange  (Leu --+ Met)  in epitope  2, position  18 of Bet v 
11, whereas  the same  exchange led to nonreactivity in re- 
sponse to Bet v  11 in TCC XPF7. In other TCC, a discrep- 
ancy between the capacity ofisoforms to induce T  cell pro- 
liferation could be observed, in spite of apparently identical 
epitope sequences (e.g., TCC XPD22,  epitope  1, isoforms 
a  and b).  This  phenomenon was reproducible.  A  possible 
explanation  could be a different treatment  of the  isoforms 
during  antigen  processing  due  to  diverse  cleavage  sites, 
leading to the creation of distinct peptides with variable an- 
tigenicity.  Table  2  shows  the  relative  potency of Bet  v  1 
isoforms a, b, d, e, and 1 in inducing proliferation of Bet v 
1-specific  TCC,  taking  nBet v  1  as  a  reference  (100%  T 
cell reactivity). 
SPT.  The  capability  of the  recombinant  Bet  v  1  iso- 
forms  to  elicit  cutaneous  reactions  was  evaluated  for five 
birch pollen-allergic patients. Using Bet v  ld, two patients 
showed  a  negative  SPT  and  three  patients  showed  ex- 
tremely weak skin reactivity.  Similar results were obtained 
with Bet v  11. As expected from in vitro results,  isoforms a 
and e consistently produced stongly positive wheal and flare 
reactions in SPT, whereas  isoform b  showed intermediate 
skin  reactivity  (Fig.  5).  In  none  of the  individuals  could 
late-phase reactions of the skin be observed. The calculated 
wheal areas reflecting the  allergenicity of Bet v  1 isoforms 
are compared in Table 2. 
Discussion 
In  this  study,  we  compared  isoforms  of an  important 
atopic  allergen  with  respect  to their  T  cell activation po- 
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tency  and  IgE-binding  capacity  (allergenicity).  Nine  iso- 
forms of Bet v  I  (27), the major allergen of birch pollen (6, 
7),  were  cloned  and  produced  as  recombinant  vlonfusion 
proteins in E. coli (Fig.  1). Although these isoforms showed 
high sequence similarity,  they revealed striking differences 
in their IgE-binding properties;  that is,  some isoforms dis- 
played  high  binding  activity,  whereas  others  showed  ex- 
tremely low reactivity.  Interestingly, this pattern was simi- 
lar for all  30 patients tested.  Based on our experiments,  we 
grouped Bet v  1 isoforms into three classes:  molecules with 
high IgE-binding activity (isoforms a,  e, and j), intermedi- 
ate  IgE-binders  (isoforms  b,  c,  and  f),  and  proteins  with 
low/no  IgE-binding capacity (isoforms d,  g, and 1)  (Fig.  2 
and Table 2).  Representatives  of each group were selected 
for further experiments  with T  lymphocytes. Bet v  1 iso- 
forms a  and  e  were  chosen as  representatives  of the  high 
IgE-binding group.  Moreover,  Bet  v  la  seems  to be  the 
most abundant isoallergen in birch pollen.  Isoforms d and 1 
were  chosen  as  members  of the  low  IgE-binding  group. 
Bet v  lb was selected as an intermediate  IgE-binding iso- 
form. 
Each isoallergen was tested in vitro for its ability to acti- 
vate allergen-specific T  lymphocytes derived from the pe- 
ripheral  blood of birch pollen-allergic  patients.  To  ensure 
that the total repertoire ofT cell-specificities for pollen Bet 
v  1 was evaluated, proliferative responses to individual iso- 
forms were investigated using PBMC and Bet v  1-specific 
TCL. TCC were isolated and reflected the patterns seen in 
experiments with PBMC and TCL (Fig. 3).  Some patients 
seemed  to be biased  toward particular  isoforms.  All TCC 
(10 of 10) isolated from patient 6 recognized isoforms b and 
d  (Table  1),  whereas  only 3  of 10 TCC  reacted with iso- 
forms a  and 1 and  4  of 10 with  isoform  e.  Other patients 
displayed a broad range of recognition of Bet v  l  isoforms; 
that is,  their TCC recognized epitopes on all five isoforms 
tested (e.g., patients  1, 2, and 7; Table  1). Despite this vari- 
ability among individuals, however, isoform Bet v  ld showed 
high T  cell antigenicity throughout our experiments.  A to- 
tal  of 48  Th  clones from eight allergic  patients  were  ana- 
lyzed, which covered all important  T  cell epitopes  on the 
Bet v  1 molecule (14, 15, 40; Fig. 4). Considering each iso- 
form individually, the highest scores for T  cell proliferative 
responses were observed with isoforna d, followed by b, 1, 
e, and a (Table 2).  Surprisingly, Bet v  la, the isoform with 
the highest IgE-binding activity, had the lowest score for T 
cell proliferation.  Scores obtained for the low IgE-binding 
isoform d were significantly higher than scores obtained for 
isoforms with high IgE-binding activity and equal to those 
found with nBet v  1 as the stimulant. 
To demonstrate  the  clinical  relevance  of these findings, 
in vivo tests (SPT) were performed. Indeed, the potency of 
isoforms d  and 1 to induce  typical urticarial  skin  reactions 
(wheal  and  flare)  in  allergic  subjects  was  dramatically  re- 
duced  compared with  isoforms  a,  b,  and  e  and  commer- 
cially  available  test  solutions  (Fig.  5  and  Table  2).  This 
shows  that  data  obtained  from  our  in  vitro  experiments 
correlate well with the in vivo IgE-binding activity of the 
isoforms and demonstrates their functional properties lead- Figure 5.  SPT with recombinant  Bet v 1 isoforms  and commercially  available  extracts. Solid and dashed lines indicate wheal and flare (erythema)  areas, 
respectively.  A, rBet v la; E, rBet v le; B, rBet v lb; D, rBet v ld; L, rBet v 11; Bi, birch pollen extract; Gr, grass pollen extract; Hi, histamine positive 
control; Na, NaCl-negative  control. 
ing to allergic effector mechanisms. To summarize, the fol- 
lowing conclusions can be drawn:  (a) hypoallergenic Bet v 
1 isoforms d  and 1 are potent activators of allergen-specific 
T  lymphocytes from birch pollen-allergic patients;  and  (b) 
Bet v  la, the most abundant isoform in birch pollen, shows 
the highest allergenicity and low T  cell antigenicity. 
Specific  immunotherapy  (SIT)  is  an  efficient  treatment 
of patients  suffering from pollinosis  (41-43).  The  benefit 
for the patient is dependent on the dose of allergen applied, 
and  the  therapeutic  success correlates with  the  concentra- 
tion  of  allergen  given  during  the  maintenance  period, 
which is reached after a period of continuously increasing 
the  dose.  On the  other hand,  the risk of anaphylactic side 
effects also  increases  with  the  amount  of allergen  applied 
per injection.  Therefore,  it  can  be  stated  that  the  risk  of 
side effects is the crucial obstacle to reach a satisfying clini- 
cal therapy success for some patients,  and that  SIT repre- 
sents a risk for all patients treated by this method  (44).  In 
the last few years it has become evident that T  lymphocytes 
are key players in the induction and maintenance of type I 
allergy  (45-47).  Therefore,  the  allergen-specific  T  cell 
should be the target of therapeutic strategies. There is evi- 
dence that successful SIT modulates the T  cell response to 
allergens,  leading  to  a  decrease  of clinical  symptoms (48). 
Furthermore, it has been shown in mice that administration 
of peptides  representing T  cell epitopes induces  tolerance 
to the whole allergenic molecule (49,  50).  The idea behind 
this  therapy  concept  is  that,  by  treating  allergic  patients 
only with  T  cell-stimulating  sequences,  a  modulation  of 
the  allergic  immune  response  at  the  level  of the  Th  cell 
could be achieved. In addition,  IgE-mediated anaphylactic 
side effects would be avoided, because these T  cell-stimu- 
lating peptides  are  different from the  B  cell epitopes  (14, 
17),  and  therefore  no  anaphylactic  effector  mechanisms 
could be triggered. One problem concerning this therapeu- 
tic approach, however, is the manifold T  cell epitopes har- 
bored  by  different  allergens  that  are  differentially  recog- 
nized by individual allergic patients (10-19). 
Taking all these aspects into consideration, we propose a 
novel approach  in  SIT  of type  I  allergy:  the  use  of full- 
length molecules with no or very low IgE-binding activity, 
but containing all T  cell-reactive domains. Such molecules 
may occur naturally,  as shown here to be the  case for the 
major allergen Bet v  1.  Bet v  1 binds IgE in  >95% of all 
birch  pollen-allergic  individuals  (>65%  react  exclusively 
with this molecule; 7): for these patients, a combination of 
isoforms d  and 1 could be used for SIT. Alternatively, suit- 
able molecules may be produced by means of genetic engi- 
606  Human IgE and T Lymphocyte Reactivity of Bet v 1 Isoallergens neering.  For example,  single  amino  acid substitutions  ob- 
tained by site-directed mutagenesis can dramatically change 
IgE-binding activity of  allergens without altering their abil- 
ity to stimulate allergen-specific TCC  (Ferreira,  F., unpub- 
lished  results).  This  approach for desensitization  combines 
the advantage of low risk of IgE-mediated side effects with 
the possibility of down regulation  of a broad repertoire  of 
T  cell specificities.  High antigen doses lead to a modulation 
of the quality of the T  lymphocyte response to the allergen 
(51, 52). It can be presumed that this T  cell-targeted thera- 
peutic strategy will function via a reduction of the secretion 
of IL-4 by lymphocytes of the Th2 type and lead to an im- 
provement of the clinical efficacy of SIT. 
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